Loading…
Glaukos Corporation entered into a definitive agreement to acquire DOSE Medical Corporation for $2.5 million in cash plus performance-based consideration. DOSE Medical develops sustained-release drug delivery platforms for retinal diseases. The transaction is expected to close in the current quarter.